News News Details

倚锋资本荣膺“2019年度最受LP青睐投资机构“

Date: 2019-12-21
Views: 51

倚锋资本荣膺“2019年度最受LP青睐投资机构“

2019年12月21日,由投资家网主办,中国科技金融促进会风险投资专业委员会协办“2019中国股权投资年度峰会”在北京东城喜来登酒店隆重举行。


本次峰会上,投资家网联合中国风投委揭晓了“2019年度系列榜单”,倚锋资本凭借在生物医药领域的持续深耕和出色的业绩荣获“2019年度最受LP青睐投资机构”。



实力上榜实至名归



峰会以“聚势待发”为主题,深度剖析股权投资全新业态,中国科技金融促进会风险投资专业委员会秘书长林宁、全国社保基金理事会原副理事长王忠民与200+政府代表、300+投资同行、100+上市公司、50+引导基金与母基金代表以及1000余位投资精英共同参与盛会。


倚锋资本荣誉上榜“2019年度最受LP青睐投资机构”,同时获评该奖的还有IDG资本、达晨财智、红杉中国、深创投、软银中国等多家实力机构。


倚锋资本荣膺“2019年度最受LP青睐投资机构“


为什么受LP青睐?


聚焦垂直细分领域



倚锋资本自2012年开始,专注全球生物医药投资,用全球视野深挖整合生物医药项目资源,至今已募集并管理5只生物医药专项基金和两只美元基金。


成功上市的案例包括微芯生物、亚盛医药、普门科技、Aridis、万春药业等。还投资了前沿生物、海普洛斯、诺尔康、荃信生物、Centrexion、Apexigen等境内外优质生物医药企业。


由于在美国市场连续投出多家优质创新药企,世界顶级期刊《Nature》对倚锋资本进行了关于原创药投资的主题专访。



以价值创造者为本



“以创业者为中心,以价值创造者为本”是倚锋的理念,董事长朱晋桥认为投资就是投人,好的创新药企团队要有丰富的研发经验,对行业的深刻理解,强大的商务能力和长远的眼光。


在投资原则上,倚锋也是坚持原创,即企业需要输出原创,构建自主研发产品管线,建立起技术壁垒,长期获利。



打造全球化的专业团队



倚锋资本还着力打造了一支全球化的专业团队,投资团队主要由中国、美国、欧洲、日本等一流名校生物医药类专业博士领军。


团队成员也具有多元化的行业背景以及全球化的视角。这支团队是生物医药领域经验最丰富的专业团队之一。


倚锋资本荣膺“2019年度最受LP青睐投资机构“


2019年,倚锋资本及合作的母基金、政府引导基金、渠道伙伴在波诡云谲的环境中披沙沥金,坚定地以创业者为中心,助力医药产业发展;未来,倚锋资本将坚守初心,继续成为最有价值的投资机构,为生命科学奋斗!



Related News / Recommended news More
2022 - 08 - 10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnos...
2022 - 08 - 05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution...
2022 - 08 - 01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of ...
2022 - 07 - 25
On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumon...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务